本帖最后由 老马 于 2012-1-13 21:20 编辑 # h. c9 W* y5 P; Q5 g) m \* e
7 ?! x6 l6 d2 W) ^
爱必妥和阿瓦斯丁的比较
, { m) Z: {" B0 H& g
- M2 @) H. J% j- N. s% k/ E* `
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/+ J3 K4 f9 p6 A8 d6 i0 t
8 {' J$ t1 O5 c+ Y. _7 P
) W0 N! T+ g0 d5 n% d
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/; j O+ [1 ]# K% C& E
==================================================
% W% R/ k0 [$ [9 B8 ZOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)$ t* ?& v; S% ^% e
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.; C' Q. G2 S" F+ G# z4 k* Z
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 i7 x5 i( V0 I# X7 c
|